Mass spectrometric and high-performance liquid chromatographic studies of medroxyprogesterone acetate metabolites in human plasma

https://doi.org/10.1016/0378-4347(91)80590-9Get rights and content

Abstract

Medroxyprogesterone acetate (MPA) treatment has been shown to exert several beneficial effects in cancer patients. It has been suggested that such effects are due in part to the metabolites derived from MPA in vivo. The first results are reported on the identification of 2α-hydroxy- and 21-hydroxy-MPA, 20-dihydro-MPA, 17α-acetoxy-2α,3β-dihydroxy-6α-methylpregn-1,4-dien-20-one and two X,21-dihydroxy-MPAs, one of them presumably being 6α-hydroxymethyl-21-hydroxy-MPA, in patient's plasma by high-performance liquid chromatographic (HPLC), gas chromatographic—mass spectrometric and NMR methods. Additionally, the presence of other metabolites such as di- and tetrahydro-MPAs and 6,21-dihydroxy-MPA, found in urine and other samples, was demonstrated in plasma. For routine clinical examinations an HPLC method is described for determination of, e.g., the unreduced MPA metabolite group in Sep-Pak-ODS column extracts of patients' plasma.

References (22)

  • D.K. Fukushima et al.

    Steroids

    (1979)
  • F. Martin et al.

    J. Steroid Biochem.

    (1980)
  • H. Adlercreutz et al.

    J. Steroid Biochem.

    (1975)
  • J.M. Cooper et al.

    Steroids

    (1968)
  • F. Martin et al.

    J. Steroid Biochem.

    (1977)
  • J.C. Babcock et al.

    J. Am. Chem. Soc.

    (1958)
  • G. Sala et al.

    Acta Endocrinol.

    (1958)
  • H.A. Nash

    Contraception

    (1975)
  • F. Pannuti et al.

    IRCS Med. Sci.

    (1977)
  • K.-D. Schulz et al.
  • J.S. Fraser et al.

    Med. J. Aust.

    (1981)
  • Cited by (0)

    1

    Permanent address: The Upjohn Co., Kalamazoo, MI, U.S.A.

    View full text